Croatia

Croatia has emerged as a high-growth life sciences hub in Southeast Europe, anchored by a deep-rooted legacy in pharmaceutical manufacturing and a rapidly modernizing biotechnology sector.

The country is best known globally for the discovery of azithromycin, a breakthrough that solidified its reputation for world-class small molecule R&D and high-standard production.

Today, the ecosystem is dominated by industry giants like Pliva (part of Teva) and innovative biopharmaceutical players focusing on biosimilars and complex generics.

Beyond traditional medicine, Croatia is accelerating healthcare innovation through a vibrant healthtech startup scene, supported by specialized business accelerators like NetHub.

The medical device industry is gaining international traction, particularly in advanced diagnostics, telemedicine solutions and robotics for orthopedics.

Academic research remains a cornerstone, with the University of Zagreb and the Ruđer Bošković Institute leading cutting-edge projects in molecular biology, immunology and genomics.

Croatia’s strategic participation in the European Research Area and Horizon Europe ensures a steady pipeline of cross-border scientific collaboration and clinical trial excellence.

With modern, EU-funded research infrastructure and a highly skilled workforce, the nation offers a competitive environment for early-stage clinical research and contract development and manufacturing (CDMO) services.

This synergy between historic expertise and digital-forward medtech makes Croatia a vital destination for global investors seeking agile R&D and scalable healthcare solutions.